Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Carcinoma, Renal Cell × testosterone undecanoate × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Hypogonadism 3 Eunuchism 2 Testicular Neoplasms 1 Prostatic Neoplasms 1 Prostate Cancer Recurrent 1 Neoplasm Metastasis 1 Klinefelter Syndrome 1 Infertility 1 Fatigue Syndrome, Chronic 1 Carcinoma, Renal Cell 1

Interventions

Nivolumab 129 pembrolizumab 114 Sunitinib 107 Everolimus 63 Bevacizumab 63 Sorafenib 62 cabozantinib 59 pazopanib 55 Ipilimumab 54 Axitinib 49 aldesleukin 47 Magnetic Resonance Spectroscopy 39 Cyclophosphamide 36 Interleukin-2 33 Radiosurgery 32 Interferon-alpha 32 lenvatinib 30 Specimen Handling 26 temsirolimus 23 atezolizumab 23 belzutifan 21 fludarabine phosphate 20 Gemcitabine 20 Radiotherapy 17 Interferon alpha-2 16 Biopsy 16 fludarabine 15 durvalumab 15 avelumab 15 Paclitaxel 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03379012 2019-10-22

FARETES

Kidney Cancer Research Bureau

Phase 2 Completed

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡